Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023

Fineline Cube Oct 19, 2023

China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

Company R&D

WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain

Fineline Cube Oct 19, 2023

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...

Company Deals

AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development

Fineline Cube Oct 19, 2023

AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...

Company Drug

Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA

Fineline Cube Oct 19, 2023

Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services

Fineline Cube Oct 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management

Fineline Cube Oct 19, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Company

Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand

Fineline Cube Oct 19, 2023

Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...

Company Drug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

Fineline Cube Oct 19, 2023

Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...

Company Deals

Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio

Fineline Cube Oct 19, 2023

US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...

Company Deals

Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia

Fineline Cube Oct 18, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...

Company Drug

MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia

Fineline Cube Oct 18, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical...

Company Drug

GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023

Fineline Cube Oct 18, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Novartis Launches Leqvio in China at RMB 9,988 per Shot

Fineline Cube Oct 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...

Company Drug

Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034

Fineline Cube Oct 18, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...

Company Deals R&D

Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development

Fineline Cube Oct 18, 2023

German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...

Company Medical Device

Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Oct 18, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Drug

BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC

Fineline Cube Oct 18, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...

Company Deals

Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications

Fineline Cube Oct 18, 2023

Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision...

Posts pagination

1 … 412 413 414 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.